Efficacy of Jiedu formula as adjuvant therapy for early recurrence of hepatocellular carcinoma after radical surgery: a propensity score matching study.
Year: 2025
Type: article
Abstract: OBJECTIVE: To investigate the clinical efficacy of using a Jiedu formula as an adjunctive therapy in patients with hepatocellular carcinoma (HCC) after hepatectomy. METHODS: 239), with the Jiedu formula administered twice a day to the patients in the THM group. The primary outcome was recurrence-free survival (RFS). Univariate and multivariate Cox regression analyses were performed to identify the prognostic factors associated with RFS. Then, the high risk of recurrence among patients was identified, and propensity score matching (PSM) and RFS analysis were performed to analyze the prognostic factors for the outcomes of patients at a high risk of recurrence in different groups. RESULTS: 26.4%, respectively. CONCLUSION: In this study, THM was found to be an effective agent for adjuvant therapy for HCC to prevent early recurrence of HCC after hepatic resection.
Source: PubMed
Authors: Feng Qiuting, H U Jiajia, Y U Song, Zhu Huirong, Cheng Simo, Zhai Xiaofeng
Language: English
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W4408957177